-+ 0.00%
-+ 0.00%
-+ 0.00%

Wellgistics Partners with Protega to Expand Access to Abuse-Deterrent Opioid Pain Medication, Support Pharmacist Education, Distribute ROXYBOND to Independent Pharmacies Nationwide

Benzinga·03/04/2025 12:46:31
Listen to the news

Wellgistics Health, Inc. (NASDAQ:WGRX, the ", Company", ))), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, is collaborating with Protega Pharmaceuticals Inc. ("Protega"). Protega is the innovative specialty pharmaceutical company that launched ROXYBOND™ (oxycodone hydrochloride), the first and only FDA-approved abuse-deterrent immediate-release (IR) opioid pain medication in the U.S. The collaboration is meant to support pharmacist education on abuse-deterrent pain management options and regulatory compliance as well as increase patient access to ROXYBOND™ for appropriately prescribed patients.

Wellgistics LLC is a pharmaceutical wholesaler and National Association of Boards of Pharmacy ("NABP") authorized distributor that serves over 5,400 independent pharmacies across all 50 states. The relationship will support education to these pharmacies and help provide distribution of ROXYBOND™ to appropriately prescribed patients, particularly in underserved and rural areas where Wellgistics LLC's independent pharmacy clients play a critical role in patient care.